# Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

> **NCT03808688** · PHASE4 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 261 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** Netarsudil Ophthalmic Solution 0.02%

## Key facts

- **NCT ID:** NCT03808688
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-27
- **Primary completion:** 2019-07-26
- **Final completion:** 2019-07-26
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03808688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03808688, "Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03808688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*